{"filing":{"accession_number":"0001776985-26-000069","cik":"0001776985","ticker":"BNTX","company_name":"BioNTech SE","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"form6-kesmo202619oct2026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000069/form6-kesmo202619oct2026.htm"},"events":[{"id":35942,"run_id":33130,"accession_number":"0001776985-26-000069","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This exhibit is a press release announcing BioNTech's presentation of clinical trial data at the ESMO 2026 Congress, featuring 16 abstracts across multiple oncology programs. The disclosure highlights late-stage pipeline progress for key candidates (pumitamig, elfetabart drozuntecan, gotistobart, and others) with new Phase 2 data from global trials in lung cancer, breast cancer, neuroendocrine neoplasms, and other solid tumors. While not a discrete M\u0026A, financing, or governance event, this represents material operational and strategic progress in the company's clinical development pipeline that would affect a reasonable investor's assessment of BioNTech's oncology prospects and competitive positioning.","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40177,"accession_number":"0001776985-26-000069","item_number":"EX-99.1","item_title":"a991261019_bntxxesmoxcrxpr.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a press release announcing BioNTech's presentation of clinical trial data at the ESMO 2026 Congress, featuring 16 abstracts across multiple oncology programs. The disclosure highlights late-stage pipeline progress for key candidates (pumitamig, elfetabart drozuntecan, gotistobart, and others) with new Phase 2 data from global trials in lung cancer, breast cancer, neuroendocrine neoplasms, and other solid tumors. While not a discrete M\u0026A, financing, or governance event, this represents material operational and strategic progress in the company's clinical development pipeline that would affect a reasonable investor's assessment of BioNTech's oncology prospects and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:27:38.610127+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40177,"accession_number":"0001776985-26-000069","item_number":"EX-99.1","item_title":"a991261019_bntxxesmoxcrxpr.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit is a press release announcing BioNTech's presentation of clinical trial data at the ESMO 2026 Congress, featuring 16 abstracts across multiple oncology programs. The disclosure highlights late-stage pipeline progress for key candidates (pumitamig, elfetabart drozuntecan, gotistobart, and others) with new Phase 2 data from global trials in lung cancer, breast cancer, neuroendocrine neoplasms, and other solid tumors. While not a discrete M\u0026A, financing, or governance event, this represents material operational and strategic progress in the company's clinical development pipeline that would affect a reasonable investor's assessment of BioNTech's oncology prospects and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:27:38.610127+00:00","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-10-19"}]}